

1638

FEATURE OF FUND

This fund aims to track the performance of TOPIX-17 Pharmaceutical Index

FUND PROFILE (as of Jul 30, 2010)

NAV (per 1 unit) ¥9,979
 Total Net Asset ¥1.2 bil.

Total No. of Holdings 33

Ticker Code 1638

Stock Exchange Tokyo Stock Exchange

Board Lot Size 1unit

Inception Date July 22, 2008

Listing Date July 23, 2008

Trust Fee Up to 0.294% annually
 See back for details.

Financial Disclosure Twice-yearly
 Dividend Date Jan. 20th and July 20th

Term of Trust Infinite

Investment Manager Daiwa Asset Management Co. Ltd.

Trustee The Sumitomo Trust & Banking Co., Ltd.

Performance

(as of Jul 30, 2010)

	1month	3months	6months	1year	3years	since inception
FUND	-0.43 %	-4.65 %	-4.24 %	-3.65 %	-----	-19.23 %
TOPIX-17 Pharmaceutical	-0.42 %	-4.73 %	-5.89 %	-6.63 %	-----	-24.11 %



Dividend Record

Settlement Term	(09.01)	(09.07)	(10.01)	(10.07)		
Dividend	152	166	159	169		
NAV (JPY)	10563	10278	10899	9809		

Total dividend since inception: ¥646

Portfolio Allocation

(as of Jul 30, 2010)

Asset Allocation		Weight
Common Stock		99.6%
Stock Futures		0.0%
REIT's, Preferred Securities		0.0%
Total		99.6%
Sector Allocation		Weight
1 Pharmaceutical		99.65%
Total		99.65%

Portfolio Holdings

(as of Jul 30, 2010)

Code	TOP 20 Holdings	Weight
1	4502 TAKEDA PHARMACEUTICAL	32.1536%
2	4503 ASTELLAS PHARMA	13.3488%
3	4568 DAIICHI SANKYO	10.9392%
4	4523 EISAI	7.7756%
5	4507 SHIONOGI	5.5134%
6	4528 ONO PHARMACEUTICAL	3.8362%
7	4519 CHUGAI PHARMACEUTICAL	3.4802%
8	4535 TAISHO PHARMACEUTICAL	3.1651%
9	4151 KYOWA HAKKO KIRIN	2.4648%
10	4508 MITSUBISHI TANABE PHARMA	2.3795%
11	4530 HISAMITSU PHARMACEUTICAL	2.2018%
12	4536 SANTEN PHARMACEUTICAL	1.8951%
13	4540 TSUMURA	1.6393%
14	4555 SAWAI PHARMACEUTICAL	1.0695%
15	4506 DAINIPPON SUMITOMO PHARMA	1.0583%
16	4527 ROHTO PHARMACEUTICAL	1.0429%
17	4521 KAKEN PHARMACEUTICAL	0.8394%
18	4534 MOCHIDA PHARMACEUTICAL	0.7110%
19	4547 KISSEI PHARMACEUTICAL	0.7045%
20	4569 KYORIN HOLDINGS	0.6927%
Total		96.91%

* Fund performance assumes that dividends (before taxes) being reinvested in the fund, and is different from actual rate of return to investors.

* NAV value is calculated after deducting trust fees.

* In the graph, the value of index is modified to match the fund NAV at the time of inception.

* Fund dividend is decided by the investment management company based on dividend policy. The amount of fund dividend is not guaranteed. Dividend amount of zero is possible.

* Performance and data above are based on past information and neither guarantee or promise future performance.

**Daiwa ETF TOPIX-17
PHARMACEUTICAL**

This document is prepared by Daiwa Asset Management Co.Ltd. intended to provide information on Daiwa ETF TOPIX-17 PHARMACEUTICAL. The document is not, and should not be construed as, an offer or the solicitation of an offer to buy or sell any securities or financial products. The document is based on sources believed to be reliable but their accuracy and completeness are not guaranteed. Final decision on the investment must be taken with sole responsibility of the investor.

Risk of the Fund

Since this fund primarily invests in stocks whose prices are vulnerable, the NAV of this fund could possibly decline and cause a loss in investment, due to management uncertainty, corporate financial distress, bankruptcy, etc. The principal investment of investors thus is not guaranteed and fund contains risk that the NAV may fall below its par value. All the gains and losses accrued to the trust assets will be attributable to the beneficiaries.

Most fluctuation factors that are expected to cause NAV changes include:

1. Stock Price Volatility (Price Volatility Risks, Credit Risks, etc.): Stock price is changed based on the political and economic conditions, operating results of the issuer, market supply and demand, etc. The price of a stock may fall significantly for a short term or a long term (If the issuer becomes operationally distressed and bankrupt, no invested fund might be returned). If the stock price of the portfolio falls, the base value may fall and the amount of principal may fall below the amount invested. This fund could also occasionally have higher than normal exposure to a particular stock, and fluctuations of such stock could dramatically influence the NAV of the fund.
2. Miscellaneous (Credit Risks for money market instruments, Investment Risk of sudden market fluctuations, Risk of computer system failures, etc.). Please read the details concerning the risks including the above, which are described under the "Investment Risks" in the fund's Prospectus.

Fee Structure

Fees associated with purchase and management of the fund.

<Fees directly charged to customers>

◆ Sales Charges & Cancellation Fee:

Fees will be decided by the distributor. As distributor's fee structure differs from each other, fee upper limit could not be informed. Please contact the distributor for detailed information.

<Fees indirectly charged during holding period>

◆ Trust fee

Trust fee is calculated as sum of 1 and 2 as shown below during the holding period.

1. Percentage of total net assets: Up to 0.294% per annum (including tax)
2. Up to 52.5% (including tax) of lending charges due to lending of stocks held in trust asset (excluding the dividend equivalent paid from stocks lent).

In case of receiving cash as pledge for lending the stocks, such amount should be calculated as 52.5% (including tax) of amount equivalent to lending charges, plus investment gains received from cash management minus the interest paid to the borrower (settled as zero if the resulted amount is of negative value).

◆ Other expenses

1. Trade mark fee as percentage of total trust asset: Upper limit is 0.02415% (including tax) as of June 26, 2008. (settled as 1.05 million Yen (including tax) when fee is lower than 1.05 million Yen (including tax)).
2. Auditing fee, commissions associated with securities transactions, etc. will be charged. (2 shall vary depending on management and other circumstances, rate of fees and their upper limits could not be informed in advance.)

The total amount of the charges, etc. above shall vary depending upon the holding period and may not be provided.

Please see further details described under "Charges and Taxes" in the Prospectus.

Information about TOPIX-17 Pharmaceutical Index and trademark of TOPIX-17 Pharmaceutical Index

- (i) The TOPIX-17 Pharmaceutical Index values specified in the Schedule hereto (hereinafter referred to as The TOPIX-17 Pharmaceutical Index) and the TOPIX -17 Series Sector Indices Trademarks are subject to the intellectual property rights owned by the Tokyo Stock Exchange, Inc. and the Tokyo Stock Exchange, Inc. owns all rights relating to the TOPIX -17 Pharmaceutical Index such as calculation, publication and use of the TOPIX-17 Pharmaceutical Index Values and relating to the TOPIX -17 Pharmaceutical Index Trademarks.
- (ii) The Tokyo Stock Exchange, Inc. shall reserve the rights to change the methods of calculation or publication, to cease the calculation or publication of the TOPIX-17 Pharmaceutical Index Values or to change the TOPIX -17 Pharmaceutical Index Trademarks or cease the use thereof.
- (iii) The Tokyo Stock Exchange, Inc. makes no warranty or representation whatsoever, either as to the results stemmed from the use of the TOPIX-17 Pharmaceutical Index Trademarks.
- (iv) The Tokyo Stock Exchange, Inc. gives no assurance regarding accuracy or completeness of the TOPIX-17 Pharmaceutical Index Values and data contained therein. Further, the Tokyo Stock Exchange, Inc. shall not be liable for the miscalculation, incorrect publication, delayed or interrupted publication of the TOPIX-17 Pharmaceutical Index Values.
- (v) Each Licensed product is managed to obtain the return linked to the performance of the TOPIX-17 Pharmaceutical Index Values; however Net Asset Value of Each Licensed Product happens not to trace the performance of the TOPIX-17 Pharmaceutical Index Values
- (vi) No Licensed Products are in any way sponsored, endorsed or promoted by the Tokyo Stock Exchange, Inc.
- (vii) The Tokyo Stock Exchange, Inc. shall not bear any obligation to give an explanation of any Licensed Products or an advice on investments to any purchaser of any Licensed Products or to the public.
- (viii) Including but not limited to the foregoing, the Tokyo Stock Exchange, Inc. shall not be responsible for any damage resulting from the issue and sale of any Licensed Products.